



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/562,200	11/08/2006	Rudolf Moser	EPROV-0024	4126
23599	7590	01/22/2008		
MILLEN, WHITE, ZELANO & BRANIGAN, P.C. 2200 CLARENDON BLVD. SUITE 1400 ARLINGTON, VA 22201			EXAMINER	
			STONE, CHRISTOPHER R	
			ART UNIT	PAPER NUMBER
			4173	
			MAIL DATE	DELIVERY MODE
			01/22/2008	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary	Application No. 10/562,200	Applicant(s) MOSER ET AL.
	Examiner CHRISTOPHER R. STONE	Art Unit 4173

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
 - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
 - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED. (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) Responsive to communication(s) filed on 07 January 2008.
- 2a) This action is FINAL. 2b) This action is non-final.
- 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) Claim(s) 1-18 is/are pending in the application.
- 4a) Of the above claim(s) 18 is/are withdrawn from consideration.
- 5) Claim(s) _____ is/are allowed.
- 6) Claim(s) 1-17 is/are rejected.
- 7) Claim(s) _____ is/are objected to.
- 8) Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) The specification is objected to by the Examiner.
- 10) The drawing(s) filed on _____ is/are: a) accepted or b) objected to by the Examiner.
 Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
 Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) All b) Some * c) None of:
1. Certified copies of the priority documents have been received.
 2. Certified copies of the priority documents have been received in Application No. _____.
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|--|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413)
Paper No(s)/Mail Date. _____. |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | 5) <input type="checkbox"/> Notice of Informal Patent Application
Paper No(s)/Mail Date _____. |
| 3) <input checked="" type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08)
Paper No(s)/Mail Date <u>2 pages</u> | 6) <input type="checkbox"/> Other: _____. |

DETAILED ACTION

Election/Restrictions

Applicant's election with traverse of Group I in the reply filed on January 7, 2008 is acknowledged. The traversal is on the ground(s) that the patent office has not established that it would pose an undue burden to examine the full scope of the claimed invention. This is not found persuasive because the instant application is a national stage entry of an international application and there is no search burden requirement in lack of unity practice. Additionally, the method claims require different search queries than the composition claims to account for their active steps. These multiple fields of search cause a search burden.

The requirement is still deemed proper and is therefore made **FINAL**.

The requirement to elect a single disclosed species of folate derivative from the list in claim 1 is withdrawn.

Claim 18 is withdrawn from further consideration pursuant to 37 CFR 1.142(b), as being drawn to a nonelected invention, there being no allowable generic or linking claim. Applicant timely traversed the restriction (election) requirement in the reply filed on January 7, 2008.

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

Claims 1, 2, 4-16 are rejected under 35 U.S.C. 103(a) as being unpatentable over Odin et al in view of Lawrence (US Patent 4931441). (Both documents listed on PTO 1449)

Claims 1, 2, 4-16 are drawn to a pharmaceutical composition comprising 5,10-methylenetetrahydrofolic acid and citrate at a pH of 7.5 to 10.5.

Odin et al teaches a composition comprising the calcium salt of 5,10-methylenetetrahydrofolic acid (CH_2FH_4) and vitamin C (ascorbic acid) at a pH of 8.95 (p. 448, 2nd column, 3rd paragraph and p. 451, 1st column, 4th paragraph) useful in the biomodulation of 5-fluorouracil (5-FU) in the treatment of cancer (p. 454, 2nd column, 2nd paragraph). The CH_2FH_4 is necessarily 6R, 6S or 6R,S, since these options contain all possibilities. Odin does not teach the composition further comprising citrate. Lawrence teaches that citrate improves the stability of the reduced folic acid derivative 5-formyl-tetrahydrofolic acid (column 2, lines 31-47). Therefore it would have been obvious to one of ordinary skill in the art at the time of the instantly claimed invention to

Art Unit: 1614

prepare the composition (or stabilize a composition of CH₂FH₄) by bringing the components together (treating the CH₂FH₄ with citrate) and adjusting the pH to 8.95, since citrate was known to improve the stability of reduced folate derivatives, thus resulting in the practice of the instantly claimed invention with a reasonable expectation of success.

Odin further teaches that tetrahydrofolic acid (FH₄) is useful for the biomodulation of 5-fluorouracil (5-FU) in the treatment of cancer (p. 454, 2nd column, 2nd paragraph). Therefore it would have been obvious to one of ordinary skill in the art at the time of the instantly claimed invention to add FH₄ and/or 5-FU to the composition mentioned above, since FH₄ and the composition were known to be used for the same purpose and 5-FU and the composition where known to be useful when administered together. Applicant is reminded of *in re Kerkhoven*, which affirmed that "It is prima facie obvious to combine two compositions each of which is taught by the prior art to be useful for the same purpose, in order to form a third composition to be used for the very same purpose.... [T]he idea of combining them flows logically from their having been individually taught in the prior art." *In re Kerkhoven*, 626 F.2d 846, 850, 205 USPQ 1069, 1072 (CCPA 1980) Additionally, it would have been obvious to one of ordinary skill in the art at the time of the instant invention to formulate the composition into a lyophilization solution and a lyophilate, since lyophilization is commonly used in the art to preserve pharmaceuticals.

Claim 3 is rejected under 35 U.S.C. 103(a) as being unpatentable over Odin et al in view of Lawrence (US Patent 4931441), further in view of Cobb et al (US Patent 5989566).

Claim 3 is drawn to a pharmaceutical composition comprising 5,10-methylenetetrahydrofolic acid, citrate and formaldehyde at a pH of 7.5 to 10.5.

Odin et al and Lawrence teach the aforementioned composition, but do not teach the composition further comprising formaldehyde.

Cobb et al teaches that formaldehyde is used as a preservative in pharmaceutical formulations (column 6, lines 1-3). Therefore, it would have been obvious to one of ordinary skill in the art at the time of the instantly claimed invention to add formaldehyde to the composition of 5,10-methylenetetrahydrofolic acid and citrate to preserve the components of the composition, thus resulting in the practice of the instantly claimed invention with a reasonable expectation of success.

Claim 17 is rejected under 35 U.S.C. 103(a) as being unpatentable over Odin et al in view of Lawrence (US Patent 4931441), further in view of Rabelink et al (US PGPUB 2002/0052374) and Binderup (US PGPUB 2002/0183277).

Claim 17 is drawn to a pharmaceutical composition comprising 5,10-methylenetetrahydrofolic acid, citrate and capecitabine at a pH of 7.5 to 10.5.

Odin et al and Lawrence teach the aforementioned composition, but do not teach the composition further comprising capecitabine.

Rabelink teaches that tetrahydrofolates are useful for increasing the therapeutic effects of fluorinated pyrimidines (paragraph [0002]). Binderup teaches that capecitabine is a fluorinated pyrimidine (paragraph [0032]). Therefore it would have been obvious to add capecitabine to the composition of Odin et al and Lawrence, to

potentiate the therapeutic effect of the drug, thus resulting in the practice of the instantly claimed invention with a reasonable expectation off success.

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to CHRISTOPHER R. STONE whose telephone number is (571)270-3494. The examiner can normally be reached on Monday-Thursday, 7:30am-4:00pm EST.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ardin H. Marschel can be reached on (571) 272-0718. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

CRS

/Ardin Marschel/
Supervisory Patent Examiner, Art Unit 1614